Li Xu

Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: July 04, 2026

FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study.

FOLFOX-HAIC versus first-line systemic chemotherapy in HBsAg-positive patients with unresectable intrahepatic cholangiocarcinoma: A propensity score matched cohort study.

Journal: Hepatobiliary & pancreatic diseases international : HBPD INT

Published: December 18, 2025

Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials.

Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 22, 2025

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.

Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma.

Journal: The Journal of clinical investigation

Published: September 23, 2025

Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study.

Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study.

Journal: Liver cancer

Published: September 10, 2025

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses.

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: a phase III trial and biomarker analyses.

Journal: Journal of the National Cancer Center

Published: September 09, 2025

Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort study.

Pathological response ≥90% predicts survival in HCC treated with neoadjuvant loco-regional therapies: A retrospective cohort study.

Journal: JHEP reports : innovation in hepatology

Published: April 14, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?

Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 25, 2025

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.

Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.

Journal: Frontiers in immunology

Published: February 08, 2025

Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma.

Transarterial Chemoembolization with Radiofrequency Ablation versus Surgical Resection for Small Late-Recurrence Hepatocellular Carcinoma.

Journal: Radiology

Published: February 04, 2025

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: January 31, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026